Protective effect of combined therapy with hyperbaric oxygen and autologous adipose-derived mesenchymal stem cells on renal function in rodent after acute ischemia-reperfusion injury.
Ischemia-reperfusion
adipose-derived mesenchymal stem cell
hyperbaric oxygen therapy
inflammation
oxidative stress
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
01
2020
accepted:
03
06
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
This study tested the hypothesis that combined hyperbaric oxygen (HBO) and autologous adipose-derived mesenchymal stem cell (ADMSC) therapy was superior to either alone at protecting renal function in rodents after acute ischemia-reperfusion (IR) injury. Adult-male SD rats (n = 40) were equally categorized: group 1 (sham-operated control); group 2 (IR + 50 μg medium intra-renal artery administration); group 3 [IR + HBO (at 1.5 h and days 1 and 2 after IR)]; group 4 [IR + ADMSC (2.0×10 Combined ADMSC-HBO therapy was superior to either one alone at protecting the kidney from acute IR injury.
Sections du résumé
BACKGROUND
BACKGROUND
This study tested the hypothesis that combined hyperbaric oxygen (HBO) and autologous adipose-derived mesenchymal stem cell (ADMSC) therapy was superior to either alone at protecting renal function in rodents after acute ischemia-reperfusion (IR) injury.
METHODS AND RESULTS
RESULTS
Adult-male SD rats (n = 40) were equally categorized: group 1 (sham-operated control); group 2 (IR + 50 μg medium intra-renal artery administration); group 3 [IR + HBO (at 1.5 h and days 1 and 2 after IR)]; group 4 [IR + ADMSC (2.0×10
CONCLUSION
CONCLUSIONS
Combined ADMSC-HBO therapy was superior to either one alone at protecting the kidney from acute IR injury.
Types de publication
Journal Article
Langues
eng
Pagination
3272-3287Informations de copyright
AJTR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
J Clin Invest. 2004 Jul;114(1):5-14
pubmed: 15232604
Clin J Am Soc Nephrol. 2015 Mar 6;10(3):500-14
pubmed: 25376763
Int J Cardiol. 2016 Aug 1;216:173-85
pubmed: 27156061
Crit Care Med. 2015 Oct;43(10):2117-32
pubmed: 26154930
Am J Kidney Dis. 2015 Feb;65(2):283-93
pubmed: 25445101
Oxid Med Cell Longev. 2018 Apr 2;2018:6012636
pubmed: 29805730
J Am Soc Nephrol. 2007 Apr;18(4):1292-8
pubmed: 17314324
J Clin Med. 2018 Dec 14;7(12):
pubmed: 30558177
Int Heart J. 2009 Mar;50(2):191-206
pubmed: 19367030
Cell Death Dis. 2018 Sep 20;9(10):965
pubmed: 30237401
Plast Reconstr Surg. 2011 Jan;127 Suppl 1:131S-141S
pubmed: 21200283
S Afr Med J. 2009 Dec 07;99(12):873-5
pubmed: 20459997
Int J Cardiol. 2015 Dec 15;201:668-83
pubmed: 26363631
Am J Transl Res. 2017 Feb 15;9(2):214-229
pubmed: 28337255
Lancet. 2005 Jan 29-Feb 4;365(9457):417-30
pubmed: 15680458
J Am Soc Nephrol. 2006 Apr;17(4):1135-42
pubmed: 16495381
Curr Opin Crit Care. 2018 Dec;24(6):483-492
pubmed: 30239411
Am J Transl Res. 2015 May 15;7(5):804-24
pubmed: 26175844
J Transl Med. 2013 Oct 25;11:270
pubmed: 24161164
Undersea Hyperb Med. 2004 Summer;31(2):193-4
pubmed: 15485079
N Engl J Med. 1996 May 30;334(22):1448-60
pubmed: 8618585
Arch Intern Med. 2008 May 12;168(9):987-95
pubmed: 18474763
Stem Cell Res Ther. 2013 May 31;4(3):62
pubmed: 23726287
J Pineal Res. 2015 Nov;59(4):434-47
pubmed: 26309060
J Pineal Res. 2014 Aug;57(1):16-32
pubmed: 24761983
Am J Transl Res. 2017 Nov 15;9(11):4756-4771
pubmed: 29218078
Vasc Med. 2008 Aug;13(3):281-91
pubmed: 18687766